Beam Therapeutics Inc
Beam Therapeutics Inc logo
BEAM

Beam Therapeutics Inc (BEAM)

$46.195.92%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$42.575
Day's Range
$46.455
$27.77
52-Week Range
$88.18
1 month return1.69%
3 month return21.54%
1 year return40.0%
5 year return43.9%

Company Information

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
OrganizationBeam Therapeutics Inc
Employees507
CEOMr. John M. Evans M.B.A.
IndustryHealth Technology

Analyst Recommendation

based on 19 analysts ratings

Buy
68%
Buy
31%
Hold
0%
Sell

Based on 19 Wall street analysts offering stock ratings for Beam Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 73.37%

Current

$46.19

Target

$80.08

Recommendation Trend

Based on 19 analyst

Current1M Ago3M Ago
Buy
13
13
14
Hold
6
6
6
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
3.0B
Book Value
$10.38
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.59
Wall Street Target Price
80.08

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
4.51
Enterprise Value
2.3B
Enterprise Value/Revenue
25.02
Enterprise Value/Ebitda
-7.67

Technicals

Beta
1.66
50 Day MA
46.99
200 Day MA
50.84

Institutional Holdings

ARK Investment Management LLC

12.05%

Vanguard Group Inc

7.45%

FMR Inc

6.81%

Temasek Holdings Ltd.

5.62%

Farallon Capital Management, L.L.C.

4.93%

State Street Corporation

4.73%

Discover more

Frequently Asked Questions

What is Beam Therapeutics Inc share price today?

Can Indians buy Beam Therapeutics Inc shares?

How can I buy Beam Therapeutics Inc shares from India?

Can Fractional shares of Beam Therapeutics Inc be purchased?

What are the documents required to start investing in Beam Therapeutics Inc stocks?

What are today’s High and Low prices of Beam Therapeutics Inc?

What are today’s traded volumes of Beam Therapeutics Inc?

What is today’s market capitalisation of Beam Therapeutics Inc?

What is the 52 Week High and Low Range of Beam Therapeutics Inc?

How much percentage Beam Therapeutics Inc is down from its 52 Week High?

How much percentage Beam Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Beam Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Beam Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*